closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA IS EFFECTIVE IN THE TREATMENT OF SKIN PLAQUES1

Significantly more patients achieved PASI-75 vs placebo at week 161,a,b

aESTEEM 1 study. Full analysis set, LOCF.

bP < 0.0001.

Response was maintained with OTEZLA through week 321

See the OTEZLA difference

Real patients, real pictures.*

Baseline

Week 16 PASI-75 result

Individual results may vary.

*Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.

 BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index.

OTEZLA SIGNIFICANTLY IMPROVES SKIN PLAQUES IN BIOLOGIC-NAÏVE PATIENTS2†

Significant PASI-75 response maintained over 2 years2,a

aLIBERATE study. ITT, LOCF.

bP <0.0001, OTEZLA vs placebo.

cIncludes patients who entered and were treated in the OTEZLA extension phase.

Response was maintained with OTEZLA for up to 2 years in biologic-naïve patients

See the OTEZLA difference

Real patients, real pictures.

Baseline

Week 16 PASI-80 result

Individual results may vary.

In biologic-naïve patients with moderate to severe plaque psoriasis.

Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.

 LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis; ITT, intent to treat.

References:

  1. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
  2. Reich K, Goodfield, M, Green L, et al. Efficacy and safety of apremilast through 104 weeks in subjects with moderate to severe psoriasis randomized to placebo, apremilast, or etanercept who continued on or switched to apremilast after week 16 on a phase 3b study. Presented at: the 2017 ACR/ARHP Annual Meeting: November 3-8, 2017; San Diego, CA.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil